As you have found, STAMPEDE's new updated website has launched. This website is a tool for stakeholders of the STAMPEDE research, assisting in such aspects as the provision of information, running of the trial and the dissemination of results. Browse the tabs and understand what is just a click away. Don't forget to check regularly for updates and keep us in your favourites! ...
The latest results from the Stampede trial in prostate cancer look to confirm a seismic shift in the treatment landscape in favour of Johnson & Johnson’s ageing Zytiga, but the impact for the whole industry – following a study run by academics – could be even more significant.
Check out the latest press, resulting from STAMPEDEs presentations across the European Society for Medical Oncology (ESMO) conference, through the EPVantage link below!
MRC Clinical Trials Unit at UCL
90 High Holborn